Johan Vingerhoets

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies
    Johan Vingerhoets
    Tibotec BVBA, Gen De Wittelaan L 11B 3, Mechelen, Belgium
    AIDS 24:503-14. 2010
  2. ncbi Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response
    Johan Vingerhoets
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Antivir Ther 18:253-6. 2013
  3. ncbi Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems
    Johan Vingerhoets
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Antivir Ther 17:1571-9. 2012
  4. ncbi Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
  5. ncbi Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies
    Lotke Tambuyzer
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:1197-205. 2010
  6. ncbi Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors
    Lotke Tambuyzer
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 14:103-9. 2009
  7. ncbi Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis
    Laurence Rimsky
    Tibotec BVBA, Beerse, Belgium
    J Acquir Immune Defic Syndr 59:39-46. 2012
  8. ncbi TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments
    Johan Vingerhoets
    Tibotec, Mechelen, Belgium
    J Virol 79:12773-82. 2005
  9. ncbi Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    AIDS 24:921-4. 2010
  10. ncbi Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine
    Lotke Tambuyzer
    Tibotec BVBA, Beerse, Belgium
    J Acquir Immune Defic Syndr 58:18-22. 2011

Detail Information

Publications13

  1. ncbi Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies
    Johan Vingerhoets
    Tibotec BVBA, Gen De Wittelaan L 11B 3, Mechelen, Belgium
    AIDS 24:503-14. 2010
    ..To refine the genotypic and phenotypic correlates of response to the nonnucleoside reverse transcriptase inhibitor etravirine...
  2. ncbi Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response
    Johan Vingerhoets
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Antivir Ther 18:253-6. 2013
    ..In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed NNRTI RAMs on virological response to an RPV- or efavirenz (EFV)-containing regimen were analysed...
  3. ncbi Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems
    Johan Vingerhoets
    Janssen Infectious Diseases BVBA, Beerse, Belgium
    Antivir Ther 17:1571-9. 2012
    ..The aims of this study were to compare various genotypic scoring systems commonly used to predict virological outcome to etravirine, and examine their concordance with etravirine phenotypic susceptibility...
  4. ncbi Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
    ..60%, respectively). ETR was equally effective in suppressing viral replication in patients infected with HIV-1 subtype B or various HIV-1 non-B subtypes...
  5. ncbi Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies
    Lotke Tambuyzer
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:1197-205. 2010
    ..Further analysis is needed to clarify the role of mutations at position 138 as determinants of etravirine resistance...
  6. ncbi Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors
    Lotke Tambuyzer
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 14:103-9. 2009
    ....
  7. ncbi Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis
    Laurence Rimsky
    Tibotec BVBA, Beerse, Belgium
    J Acquir Immune Defic Syndr 59:39-46. 2012
    ..The frequent emergence of E138K, especially in combination with M184I, in rilpivirine VFs is a unique finding of these trials...
  8. ncbi TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments
    Johan Vingerhoets
    Tibotec, Mechelen, Belgium
    J Virol 79:12773-82. 2005
    ..These results demonstrate that TMC125 has a unique profile of activity against NNRTI-resistant virus and possesses a high genetic barrier to the development of resistance in vitro...
  9. ncbi Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials
    Monika Peeters
    Tibotec BVBA, Mechelen, Belgium
    AIDS 24:921-4. 2010
    ....
  10. ncbi Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine
    Lotke Tambuyzer
    Tibotec BVBA, Beerse, Belgium
    J Acquir Immune Defic Syndr 58:18-22. 2011
    ..9, 2.4, 2.6, 3.0, 3.6, and 2.8, respectively. E138G, K, and Q were added to the existing etravirine-weighted genotypic score including 17 etravirine resistance-associated mutations...
  11. ncbi Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects
    Herta Crauwels
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 17:439-46. 2012
    ..Rilpivirine and efavirenz share metabolic pathways (CYP3A), potentially leading to drug-drug interactions. We report the pharmacokinetics, ex vivo antiviral activity and safety of rilpivirine, following efavirenz treatment...
  12. ncbi Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens
    Soumi Gupta
    Monogram Biosciences, Inc, South San Francisco, California, USA
    Antimicrob Agents Chemother 55:2872-9. 2011
    ..Since virologic responses to etravirine were not affected by CDMs, the clinical impacts of these mutations on etravirine susceptibility appear to be minimal...
  13. ncbi TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
    Koen Andries
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Antimicrob Agents Chemother 48:4680-6. 2004
    ..TMC125 is a potent next generation NNRTI, with the potential for use in individuals infected with NNRTI-resistant virus...